南京地区25家医院2012-2014年分子靶向抗肿瘤药应用分析
x

请在关注微信后,向客服人员索取文件

篇名: 南京地区25家医院2012-2014年分子靶向抗肿瘤药应用分析
TITLE:
摘要: 目的:为分子靶向抗肿瘤药的临床合理使用提供参考。方法:采用回顾性调查方法,对南京地区25家医院2012-2014年分子靶向抗肿瘤药的销售金额、用药频度(DDDs)、日均费用(DDC)及排序比(B/A)进行分析。结果:南京地区25家医院分子靶向抗肿瘤药销售金额由2012年的6 169.29万元增加至2013年的8 813.38万元,增长了42.86%,2014年下降至8 082.23万元,降低了8.3%。其中,单分子抗体药的销售金额构成比逐年下降,小分子酪氨酸激酶抑制剂的销售金额构成比逐年增长。利妥昔单抗、曲妥珠单抗各年度销售金额均排名前列。曲妥珠单抗、吉非替尼和厄洛替尼连续3年DDDs排名前3,利用频度较高。大部分药物DDC相对稳定,B/A≥1,销售金额与用药频度同步性总体较好。结论:南京地区分子靶向抗肿瘤药的临床应用合理,价格因素对该类药物的应用影响较大。
ABSTRACT: OBJECTIVE: To provide reference for rational use of molecular targeted anti-tumor drugs in the clinic. METHODS: In retrospective survey, the utilization of molecular targeted anti-tumor drugs were statistically analyzed in 25 hospitals from Nanjing area during 2012-2014 in terms of consumption sum, DDDs, DDC and B/A. RESULTS: The consumption sum of molecular targeted anti-tumor drugs increased from 6 169.29 ten thousand yuan in 2012 to 8 813.38 ten thousand yuan, increasing by 42.86%; and then decreased to 8 082.3 ten thousand yuan, decreasing by 8.3%. The consumption sum ratio of single-molecule antibody agent decreased year by year, while that of small-molecule tyrosine kinase inhibitor increased year by year. Rituximab and trastuzumab took up the front in the list of annual consumption sum. Trastuzumab, gefitinib and erlotinib remained the top 3 places in the list of DDDs and were used frequently. DDC of most of molecular targeted anti-tumor drugs kept stable relatively, and the B/A value were more than 1; their consumption sum was well synchronized with DDDs. CONCLUSIONS: The utilization of molecular targeted anti-tumor drugs is reasonable in Nanjing area. The price of drugs greatly influence their utilization.
期刊: 2016年第27卷第14期
作者: 王羽,刘慧,戴惠珍
AUTHORS: WANG Yu,LIU Hui,DAI Huizhen
关键字: 分子靶向药物;抗肿瘤药;销售金额;用药频度;应用分析;南京地区
KEYWORDS: Molecular targeted drugs; Anti-tumor drugs; Consumpiton sum; DDDs; Analysis of drug utilization; Nanjing area
阅读数: 99 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!